Terms: = Uterine cancer AND FOXP1, MGC12942, 27086, ENSG00000114861, hFKH1B, MGC99551, FLJ23741, QRF1, 12CC4, HSPC215, MGC88572 AND Prognosis
3 results:
1. NAT10/ac4C/foxp1 Promotes Malignant Progression and Facilitates Immunosuppression by Reprogramming Glycolytic Metabolism in Cervical cancer.
Chen X; Hao Y; Liu Y; Zhong S; You Y; Ao K; Chong T; Luo X; Yin M; Ye M; He H; Lu A; Chen J; Li X; Zhang J; Guo X
Adv Sci (Weinh); 2023 Nov; 10(32):e2302705. PubMed ID: 37818745
[TBL] [Abstract] [Full Text] [Related]
2. Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.
Ricci F; Fratelli M; Guffanti F; Porcu L; Spriano F; Dell'Anna T; Fruscio R; Damia G
Oncotarget; 2017 Jan; 8(5):7441-7451. PubMed ID: 26910918
[TBL] [Abstract] [Full Text] [Related]
3. Primary intravascular large B cell lymphoma of the endometrium.
Xia Y; Wang Y; Jiang Y; Yu W; Li Y; Xiang F; Wang C
Acta Histochem; 2014 Jun; 116(5):993-6. PubMed ID: 24418320
[TBL] [Abstract] [Full Text] [Related]
